ORSERDU (elacestrant), FDA Approved for ER+/HER2- Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson

CARY, N.C., Feb. 10, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Stemline Therapeutics Inc., as a limited distribution network specialty pharmacy provider for ORSERDU™ (elacestrant).

ORSERDU is an estrogen receptor antagonist indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

ORSERDU, approved by the U.S. Food and Drug Administration (FDA) on January 30, 2023, is an orally administered drug. ORSERDU's New Drug Application (NDA) was evaluated under Priority Review and supported by findings from the pivotal global Phase 3 EMERALD trial.

“ORSERDU fulfills an unmet need as a novel treatment option for patients with advanced disease harboring ESR1 mutations and is a welcomed, convenient option for patients following CDK 4/6 inhibitor use,” said Ela Lourido, vice president, Biopharma Services, Biologics by McKesson. “Biologics is proud to be chosen by Stemline Therapeutics Inc. as a specialty pharmacy provider for this much-needed medication.”

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.

For more information about ORSERDU, including full prescribing information, please click here.

ORSERDU™ is a trademark of the Menarini Group.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.